The Quest for a Cure Matt Sharp Project Inform/ATAC Tim Horn aidsmeds.com/ATAC Overview Treatment vs. Cure Sterilizing Cure Functional Cure Preventive Vaccines Treatment as Prevention Funding Advocacy 2 Treatment vs. Cure 3 Why A Cure? Chronic and manageable disease? HIV drugs, though essential for life in the absence of a cure, take a potentially lethal toll on the bodies of people with HIV, precipitating problems ranging from liver cancer to heart attacks 4 More and more people will be taking antiretroviral medications as treatment guidelines shift and treatment-forprevention programs begin rolling out Treatment fatigue will become a growing concern as well as cumulative toxicities 5 Antiretroviral drugs work well for most people but… – Some have discordant or inadequate responses for a variety of known and unknown reasons – There are some people who have run out of treatment options despite the number of approved medications 6 Antiretrovirals are only available to 40% of people who need them around the world Providing antiretroviral therapy for every person with HIV/AIDS, for the rest of their lives, is financially and logistically problematic 7 The ultimate goal for research on any disease is a cure but… – HIV cure research continues to face many challenges and complexities 8 A cure would save federal dollars – The US currently spends $11 billion annually on caring for people with AIDS in the US, and in 2008 spent $6 billion on its successful US global AIDS program Would also allow some of the one million people living with HIV in the US to return to work and paying taxes 9 Different Possible “Cures” Sterilizing cure: eliminating all HIV from the body Functional cure: permanent viral suppression without therapy Preventive vaccines Treatment as prevention: universal, widespread use of treatment to radically reduce risk of HIV transmission 10 Sterilizing Cure 11 The Hope 1995: David Ho and others suggest HIV eradication with early use of drug combinations, much like approach used to cure diseases like TB and leukemia One and a half to three years of treatment necessary to kill off two HIV compartments: – Free HIV and actively infected CD4s – chronically infected cells (macrophages and dendritic cells) 12 The Reality 1997: Three teams discover third compartment – Resting, latently infected CD4 memory Tcells potentially lasting a lifetime 13 Ongoing viral replication – Intensifying treatment further reduces VL – Chronic inflammation What’s causing this? – Incomplete viral suppression? – Intermittent production by stable cells? – Anatomical reservoirs (brain, gut, etc.) 14 Treatment Intensification Older Approaches Ziagen (abacavir) Protease inhibitor NNRTI Newer Approaches Maraviroc Selzentry 15 Purging the Reservoir Older Approaches IL-2 IL-2 and interferon-g OKT3 and IL-2 Newer Approaches IL-7 HDAC inhibition – Valproic acid Prostratin HMBA 16 17 D. D. Richman et al., Science 323, 1304 -1307 (2009) Therapeutic Vaccines Activate transcription of proviral DNA in the presence of ARV treatment 18 Gene Therapy Berlin bone marrow transplant case Anti-HIV ribozymes Antisense siRNA Zinc-finger nucleases TRIM5a Note: Myleoablative conditioning likely required 19 Is HIV eradication practical? With advances in HIV therapy, is striving for HIV eradication in more than a few specific cases worth the drastic interventions likely to be required to accomplish this? Are there simpler approaches? 20 Functional Cure 21 Learning from LTNPs Lessons from long-term nonprogressors and elite controllers – Elite controllers: <1% of PLWHIV – 50% have strong HIV-specific CD8 cells – Other possibilities: NK cells, low CCR5 expression, skewed HLA-C expression, low immunoregulatory response 22 Early HIV Treatment ARV therapy started during acute and early HIV infection – Can it protect immune function? – Does it result in lower viral load “set point?” 23 Therapeutic Vaccines Training the immune system to better respond to HIV in the absence of ARV treatment – An effective preventive vaccine could potentially work as a therapeutic vaccine, and vice versa 24 Older Approaches Whole inactive virus Newer Approaches Prime-boost (GeoVax) – Remune Virus-derived gp160 Cell-derived gp160 Canarypox-based – HIV DNA primer – MVA (smallpox) booster Vacc-4x (Bionor Immuno) – ALVAC 1452 25 STIs Encouraging initial results – Berlin Patient – Small studies Discouraging follow-up results – Danger in MDR HIV – No proven benefit – SMART study 26 Future of STIs – In combination with immune-based therapies? – Will these be allowed by FDA? 27 Preventive Vaccines 28 The Big Picture By inoculating populations HIV would be stopped Humoral vs cellular responses Several vaccine candidates have failed STEP Merck trial interrupted and discontinued RV 144 adenoviral candidate showed 31% efficacy-trials are ongoing Huge, expensive trials with large cohorts and complicated science 29 Treatment as Prevention 30 Can universal testing and treatment snuff out HIV? TLC+ framework 31 Funding 32 National Institutes for Health is the largest funder of AIDS research in the world yet is underfunded 33 Budget of the NIH has essentially been flat funded since 2003, and in constant dollars lost 13.4% of its annual spending power by 2009 due to biomedical inflation 34 President Obama’s 2011 proposed budget would add only 3% to the overall NIH budget, a continued decline in spending power Due to the current economic crisis, President Obama dedicated $10 billion in Stimulus Package funds to NIH research, and about 1/10 of this was designated to NIAID (National Institute of Allergy and Infectious Diseases). 35 NIAID announced that a portion of these funds would be used for basic research into viral persistence—HIV eradication Fauci has put cure research as one of the top of the NIAID research agenda 36 Advocacy 37 Cure Mobilization – education – misinformation – complex information – new Bogus cures More research dollars 38 IBT Strategy Group Michael Palm Basic Science, Vaccines & Prevention Project Weblog Project Inform www.projectinform.org HIV Policy Project www.aidspolicyproject.org 39